Programme

Download PDF programme

DAY 1 - MONDAY MAY 31^st, 2021

SESSION I - BIOREAGENTS - Chairmen: Paolo Dellabona & Carole Guillonneau

• 2 pm   IL-2-based immunotherapies for (dis)-engaging Tregs - Eliane Piaggio, Translational immunotherapy team U938, Institut Curie, Paris
• 2:30 pm  Oncolytic activity of attenuated Measles virus and the defects in the type I interferon response in cancer - Jean-François Fonteneau, CRCINA, INSERM U1232, LabEx IGO, Siric ILIAD, Nantes
• 3 pm   Harnessing Innate Immunity in Cancer Therapy - Eric Vivier, Aix Marseille University, APHM, CNRS, INSERM, CIML / Hôpital de la Timone, Marseille-Immunopole / Innate Pharma Research Laboratories, Marseille, France
• 3:30 pm   Targeting Trained Immunity in Organ Transplantation - Jordi Ochando, Icahn School of Medicine at Mount Sinai, New York City, USA
• 4 - 4:30 pm   Short break

SESSION II - ADVANCED CELL THERAPY - Chairmen: Dimitrios L. Wagner & Nathalie Labarrière

• 4:30 pm   IL-10-producing dendritic cell biology and their applications to control unwanted immune responses - Silvia Gregori, San Raffaele Telethon Institute for Gene Therapy, Milan, Italy
• 5:00 pm   Neoantigen specific CD4+ T cells that infiltrate human melanoma exist in diverse differentiation states and correlate with activation of CD8+ T cells, macrophages, and B cells - Stanley Riddell, Fred Hutchinson Cancer Research Center, Seattle, USA
• 5:30 pm   Reprogramming Human Immune Cells with CRISPR - Alexander Marson, University of California, San Francisco, USA

• 6:00 pm   Keynote speech- Human T cell differentiation epigenomic atlas and T cell exhaustion - John Wherry, University of Pennsylvania, Philadelphia, USA

DAY 2 - TUESDAY JUNE 1^st, 2021

9:30 am - 12:00 pm Selected communications  (10 min each + 5 min for questions)

Chairmen: Sophie Brouard & Mikaël Roussel

• 9:30 am  Enhancing CAR T-cell therapies with precision genome engineering – Laurent Poirot, Cellectis
• 9:45 am   Immunosuppressant-resistant T cell products for improved functionality in immunosuppressed patients - Leila Amini, Berlin Institute of Health, Center for Regenerative Therapies, Berlin Center for Advanced Therapies, Charité Universitätsmedizin Berlin – CVK
• 10:00 am   Critical Role of the Regulatory Cytokine IL-34 in Treg Function – Ignacio Anegon, CRTI, UMR 1064 INSERM, Nantes Université
• 10:15 am   Human microbiota-induced TREGS : potential roles in homeostasis and diseases - Emmanuelle Godefroy, CRCINA, UMR1232 INSERM, Nantes Université
• 10:30 am   Role of the C-type lectin CLEC-1, a novel immune checkpoint in DC1 cross-presentation and anti-tumor response - Marion Drouin, CRTI, UMR 1064 INSERM, Nantes Université
• 10:45 am   Agonist anti-ChemR23 mAb blunts tissue neutrophil accumulation and triggers chronic colitis inflammation resolution - Charlène Trilleaud, OSE Immunotherapeutics, Nantes
• 11:00 am   Blocking PDGFRα signaling ameliorates multiple sclerosis-like neuroinflammation by inhibiting disruption of the blood brain barrier - Manuel Zeitelhofer, Karolinska Institute, MBB, Vascular Biology Unit, Stockholm, Sweden
• 11:15 am   The myeloid lineage is required for the emergence of a regeneration permissive environment following Xenopus tail amputation - Jerome Jullien, Wellcome Trust/Cancer Research UK Gurdon Institute, University of Cambridge, Cambridge, UK
• 11:30 pm Impact of inflammation on the specific CD4+ T cell and antibody responses during antigen expression in the mouse liver - Anaïs Cardon, CRTI, UMR 1064 INSERM, Nantes Université
• 11:45 pm  Characterizing the BK polyomavirus-specific B-cell repertoire in kidney transplant recipients with BK reactivation - Dorian McIlroy, CRTI, UMR 1064 INSERM, Nantes Université

SESSION III - NEW HORIZONS - Chairmen: Megan Sykes & Catherine Rabu

• 1:45 pm   Deep Profiling of Tissue Ecosystems by Imaging Mass Cytometry - Nicolas Damond, Department of Quantitative Biomedicine, University of Zurich, Switzerland
• 2:15 pm   Mesenchymal stromal cell heterogeneity: implication for their clinical application - Karin Tarte, Inserm U1236, University of Rennes, Rennes University Hospital, France
• 2:45 pm  Reconstructing the developing blood and immune system through single cell genomics - Laura Jardine, Biosciences Institute, Newcastle University, UK
• 3:15 pm   Targeting common epithelial malignancies with TCR engineered lymphocytes specific for 'public' neoantigens - Christopher Klebanoff, Memorial Sloan Kettering Cancer Center and the Parker Institute for Cancer Immunotherapy, New York, USA
• 3:45 - 4:15 pm   Short break

 SESSION IV - TISSUE MICROENVIRONMENT - Chairmen: Barbara Seliger & Jérôme Martin

• 4:15 pm   Immunoregulation of inflammation - Renato Monteiro, Center for Research on Inflammation - INSERM U 1149 & CNRS ERL8252 / Paris   Diderot Faculty of Medicine
• 4:45 pm   Myeloid cells and cancer immunotherapy - Antonio Sica, Dept of Pharmacological Sciences, University of Eastern Piedmont, Novara / Head lab. Molecular Immunology, Humanitas Clinical and Research Center , Milan, Italy
• 5:15 pm   TIGIT and its cellular and bacterial ligands: new checkpoints for cancer immune therapy - Ofer Mandelboim, Institute of Medical Research Israel-Canada (IMRIC), University of Jerusalem, Israel
• 5:45 pm   Immune escape mechanisms of tumors and their impact for immunotherapies - Barbara Seliger, Institute for Medical Immunology at the Martin-Luther-University Halle-Wittenberg, Germany
• 6:15 pm   Evolution of a Stromal-Immune Axis in Cancer Immunology and immunotherapy - Shannon Turley, Department of Cancer Immunology, Genentech, South San Francisco, CA, USA

• 6:45 pm   Awarding ceremony (best oral presentation, best poster)